To the best of our knowledge, this retrospective study is the first to investigate the real-world use and outcome of LCT for oligo-residual NSCLC patients at the best response of first-line PD-1/PD-L1 inhibitors treatment. Here, CD274 is linked to non-small cell lung carcinoma.